本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
XINYU, China, Jan. 25, 2024 /PRNewswire/ -- Planet Image International Limited ("Planet Image" or the "Company") (Nasdaq: YIBO), an export-oriented manufacturer and seller of compatible toner cartridges based in China, the U.S. and Europe, today announced the pricing of its initial public offering of 1,250,000 Class A ordinary shares at a public offering price of US$4.00 per share for total gross proceeds of approximately US$ 5 million, before deducting underwriting discounts and offering expenses payable by the Company. The Class A ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on The Nasdaq Capital Market under the ticker symbol "YIBO" on January 25, 2024. The Company has granted the underwriter a 45-day option to purchase up to an additional 187,500 Class A ordinary shares at the public offering price, less underwriting discounts. The offering is expected to close on January 29, 2024, subject to customary closing conditions. The Company intends to use the net proceeds from the offering for: i) constructing a comprehensive, multi-layer production center; ii) research and development; iii) updating the software systems of the Company's own websites; iv) setting up additional warehouses in overseas locations; and v) general corporate purposes. US Tiger Securities, Inc. is acting as the sole book runner for the offering. Hunter Taubman Fischer & Li LLC is acting as U.S. counsel to the Company. VCL Law LLP is acting as U.S. counsel to the underwriter. A registration statement on Form F-1, as amended (File No.333- 263602) (the "Registration Statement"), relating to the offering, was filed with the U.S. Securities and Exchange Commission ("SEC") by the Company and declared effective by the SEC on January 24, 2024. The offering is being made only by means of a prospectus, forming a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus related to the offering may be obtained, when available, from US Tiger Securities, Inc., by standard mail to US Tiger Securities, Inc., 437 Madison Avenue, 27th Floor, New York, New York 10022, or by telephone at +1 646-978-5188. Before you invest, you should read the final prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Planet Image International Limited Planet Image International Limited is an export-oriented manufacturer and seller of compatible toner cartridges based in China, the U.S. and Europe. It primarily develops and manufactures toner cartridges that are compatible with, and can be used in, a wide range of commonly available models of laser printers from different manufacturers, or compatible toner cartridges, on a white-label or third-party brand basis or under its self-owned brands. It also sells its branded products through online sales channels under three brands, TrueImage, CoolToner, and AZtech. Its mission is to deliver high-quality and cost-effective printing solutions to consumers around the world with its proprietary technology, research and development capabilities and its integrated and localized sales, logistics and service platform. More information, please visit http://www.yibomk.com/. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact in this press release are forward-looking statements, including but not limited to, the offer and sale of shares, the terms of the Company's proposed offering, the intent, belief or current expectations of Planet Image and members of its management, as well as the assumptions on which such statements are based. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC. For more information, please contact: Investor Relations:Sherry ZhengWeitian Group LLCPhone: 718-213-7386Email: shunyu.zheng@weitian-ir.com
SUZHOU, China, Jan. 25, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and 3DMedicines (stock code: 1244.HK) ("Licensors") announced that we entered into a license agreement with Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296，NSE: GLENMARK) for the subcutaneous injection PD-L1 antibody drug (R&D code: KN035, generic name: Envafolimab), pursuant to which, Glenmark was granted exclusive licensing interests in clinical development and commercialization of oncology indications in India, Asia Pacific(except Singapore, Thailand, Malaysia), the Middle East and Africa, Russia, CIS and Latin America. Glenmark will develop and commercialize KN035 in the Field in the Territory at its own cost and expense. Under the License Agreement, Licensors will receive from GSSA (a) a total of up to US$700.8 million of a non-refundable upfront payment and milestones payments subject to the achievement of certain development, regulatory and commercialization milestones, and (b) a single to double digits percentage royalty fee according to the level of net sales of KN035. The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between Jiangsu Alphamab and 3D Medicines.Jiangsu Alphamab retains its sole right to manufacture KN035 for any purpose within or outside the Territory. 3D Medicines retains the right to develop and commercialize KN035 for any purpose in the field of tumor outside the Territory. We believe that the cooperation will enable Jiangsu Alphamab to effectively utilize the existing team and resources of Glenmark and establish a favorable market position for KN035 in the Territory rapidly. The implementation of the License Agreement will have a positive impact on the commercialization of KN035 in the Territory. Dr. Ting Xu, Chairman, and CEO of Alphamab Oncology, remarked, "This collaboration holds significant importance for the continued advancement of Envafolimab. Leveraging Glenmark's robust development and commercialization capabilities, we are confident that Envafolimab will reach a substantial number of patients in the specified territory, especially in regions where cancer patients face underserved conditions. The notable advantages of Envafolimab in terms of safety, convenience, and compliance position it as a competitive product. We eagerly anticipate a successful collaboration." Dr. Gong Zhaolong, Chairman and CEO of 3D Medicines, remarked, "We are very pleased that Envolizumab can help more cancer patients. This cooperation is good news for more cancer patients. In a wide range of emerging markets, patients need more convenient and innovative treatments. We will work together to serve more cancer patients and help them live longer and better." "This marks an important milestone for us at Glenmark, through this transformational deal we get access to the first recombinant humanized single domain antibody against PD-L1 in a SubQ formulation for a wide territory globally. We are excited to take this innovative product across our territory and meaningfully contribute to the spread of immune Oncology treatments to potentially help cancer patients across emerging markets." remarked Glenn Saldanha, Chairman & Managing Director Glenmark Pharmaceuticals Ltd. About Envafolimab（KN035） Envafolimab is a single domain Fc fusion PD-L1 antibody independently invented by Alphamab Oncology，and co-developed with 3D (Beijing) Medicines since 2016. On March 30, 2020, Alphamab Oncology, 3DMed, and Simcere reached a strategic cooperation, whereby Alphamab Oncology is responsible for production and quality control, and 3DMed is responsible for the clinical development in oncology field, and Simcere is responsible for the exclusive commercial promotion of products in mainland China. Based on its unique design that allows rapid subcutaneous injection, it has advantages of improved safety, convenience in drug administration, and treatment compliance. Patients do not require an intravenous infusion which lowers medical costs. At present, Envafolimab is being studied in clinical trials in multiple tumor types in China, the United States and Japan, including registration/phase III clinical trials in multiple indications. Envafolimab obtained orphan drug designation from the US FDA for the treatment of advanced biliary tract cancer and soft tissue sarcoma. In November 2021, Envafolimab obtained the market approval by the Chinese National Medical Products Administration for the treatment of MSI-H or dMMR advanced solid tumors, including those patients with advanced colorectal cancer who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens as well as patients with other advanced solid tumors who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options. About Alphamab Oncology Alphamab Oncology is a leading biopharmaceutical company committed to the discovery, development, manufacturing, and commercialization of cutting-edge biotherapeutics for the treatment of cancer. On December 12, 2019, the company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966. Our integrated platform seamlessly combines research, development, and manufacturing capabilities for biologics. We take pride in our extensive intellectual property portfolio, encompassing protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification. Distinguished by a globally competitive pipeline, Alphamab Oncology specializes in antibody-drug conjugation, single domain antibody/monoclonal antibodies, and multi-functional antibodies. Notably, Envafolima, the world's first subcutaneously injectable PD-L1 inhibitor, received approval from Chinese authorities in 2021, offering widespread accessibility to cancer patients. Three additional products are currently in the advanced stages of clinical development, with KN026 having earned Breakthrough Designation from the China National Medical Products Administration. Furthermore, we have cultivated a series of early-stage assets, including two in Phase I development. Our overarching mission is to enhance the manageability and curability of cancer by addressing unmet medical needs in oncology. Alphamab Oncology is dedicated to the development of safe and affordable drugs, leveraging a global competitive edge.
BANGKOK and HO CHI MINH CITY, Vietnam, Jan. 25, 2024 /PRNewswire/ -- Technosoft Automotive, a leading provider of cutting-edge automotive solutions, is thrilled to announce the launch of its new local websites and initiate dynamic local marketing campaigns in collaboration with Microsoft AI technology. The innovative Yana Automotive Solution, integrated with Microsoft AI, aims to revolutionize dealership operations, providing an advanced and streamlined experience for dealers and customers. The newly unveiled website showcases Yana's commitment to delivering state-of-the-art technology to the automotive sector. The user-friendly interface provides easy navigation for visitors to explore the features and benefits of Yana's comprehensive solution, emphasizing its integration with Microsoft AI technology. To kickstart the Yana launch in Thailand and Vietnam, Technosoft Automotive has joined forces with two prominent local partners, Yokogawa Votiva Solutions and ABeam Consulting, who have expressed their enthusiasm and support for this groundbreaking initiative. Dinh Tien Dung, the General Director at Yokogawa Votiva Solutions, has expressed his excitement about collaborating with Technosoft Automotive. He stated they are thrilled to work together and are committed to delivering an exceptional Yana Automotive Solution (Microsoft Dynamics 365 CRM-based solution) natively integrated with Dynamics 365 Finance and Operations at the back office. With almost two decades of experience in the Southeast Asian region, Yokogawa Votiva Solutions Group has extensive knowledge of local accounting practices, regulations, and cultures beyond Vietnam and Thailand. This knowledge makes them well-positioned to provide locally compliant solutions tailored to different business needs. This collaboration is a powerful alliance for enterprises seeking excellence in the dynamic landscape of Southeast Asia. "The partnership between ABeam Consulting and Technosoft Automotive is a strong collaboration that brings together extensive industry expertise to aid the strategic navigation of digital transformation in the automotive sector in Vietnam and the wider region," said Mr. Ryohei Oda, Managing Director of ABeam Consulting Vietnam. He emphasized that Yana Automotive Solution is not just a new product launch, but it represents a significant value creation and a competitive advantage for automotive players in the rapidly expanding markets of Thailand and Vietnam. This partnership showcases their commitment to excellence and innovation in the region's ever-changing automotive industry. Following this successful local website launch, Technosoft Automotive is thrilled to roll out dynamic joint marketing campaigns, including events, digital outreach, and collaborative efforts with partners, spotlighting Yana's transformative benefits for local businesses. Explore Yana's groundbreaking features, aiming to revolutionize dealership operations and optimize business processes among vehicle owners, OEMs, and dealers. For an in-depth exploration and firsthand experience, visit https://technosoftautomotive.com/th-th/ and https://technosoftautomotive.com/vi-vn/. About Yana Automotive Solution: Yana Automotive Solution is a leading cloud-based platform designed for automotive enterprises. This comprehensive National Sales Company (NSC) service suite goes beyond the conventional Dealer Management System (DMS), focusing on digital marketing, finance, and supply chain functionalities. It aims to improve communication between Original Equipment Manufacturers (OEMs) and dealers, resulting in an enhanced Customer Experience (CX) and improved operational efficiency across the automotive ecosystem. For media inquiries, please contact:Marketing th.marketing@technosoftautomotive.com vn.marketing@technosoftautomotive.com
SAN DIEGO, Jan. 25, 2024 /PRNewswire/ -- A recent study published in the Research in Autism Spectrum Disorders unveils groundbreaking solutions for neurodevelopmental disorders. This is the first double-blinded, randomized, placebo-controlled trial aimed at exploring the impact of a single probiotic strain on behavioral changes in preschool children aged 2.5–7 years with autism spectrum disorder (ASD), specifically targeting the gut-brain axis (GBA). The primary objective was to determine treatment effects by assessing using questionnaires related to ASD, mood, and activity symptoms at various time points with the intervention of Lactobacillus plantarum PS128 (PS128) probiotic. This trial enrolled 86 subjects and randomly allocated them in a 1:1 ratio to either the "PS128 early use group" (E group) or the "PS128 late use group" (L group). During the first stage, the E group received PS128, while the L group received placebo for 2 months. In the second stage, all subjects received PS128 for an additional 2 months. This trial demonstrated a significant reduction in anxious/depressed problems after taking two capsules of PS128 per day, providing a total of 6 × 1010 colony-forming units, for 2 months. The L group also showed notable improvement following 2 months of PS128 intervention in the second stage. These findings provide support for the notion that a brief 2-month intervention with a high dose of PS128 effectively improved certain internalizing issues in young children with ASD. PS128 was proven to be a psychobiotic with neurotransmitter modulatory effects. Bened Life believes that PS128's positive impact on alleviating ASD-related symptoms is connected to changes in the metabolism of dopamine and serotonin in the brain. This belief is supported by previous studies showing that PS128 influences the metabolism of dopamine and serotonin in various rodent models. PS128 may also enhance the effect through its potential influence on microbial diversity. Leveraging the Gut-Brain Axis (GBA) for Neurological Disorders Management The intricate connection between the nervous system and the gastrointestinal tract is recognized as the GBA. It comprises the linkage between the central nervous system (brain), the enteric nervous system (gut), and the microbiome residing in the gut (microbiota), facilitated by the circulatory system, immune system, and the vagus nerve. The bidirectional communication between the brain and gut occurs through various channels, including nerve signals, immune molecules, hormones, and microbial metabolites. This sophisticated network underscores the dynamic interplay between neurological and gastrointestinal elements. Individuals with neurodevelopmental conditions like ASD often experience imbalances of neurotransmitters, especially in happy hormones serotonin or dopamine activity, possibly resulting from gut dysbiosis. Taking a neurologically active probiotic like PS128 may offer potential assistance in managing these imbalances. Previous clinical trials involving children and adolescents with ASD suggest a potential reduction in ASD-related neurological behaviors with the use of PS128, along with improvements in anxiety levels, shared attention, and communication skills. Other findings indicate that PS128 could offer benefits in alleviating attention deficit hyperactivity disorder (ADHD)-related symptoms without causing adverse effects. This contrasts with many ADHD medications known for their side effects, suggesting a potential advantage of PS128 in avoiding such problems. The decline in dopamine levels is associated with the aggregation of ⍺-synuclein in brain neurons that leads to the depletion of dopamine-producing neurons and the onset of motor symptoms in Parkinson's disease (PD). In addition to conventional treatment, individuals with PD experienced enhanced motor function and improved quality of life after supplementing with PS128 for 12 weeks. Notably, PS128 is considered safe to take alongside the usual dose of levodopa or other medications. Furthermore, in a preliminary trial of PS128, there was a noteworthy amelioration in the severity of depression among individuals diagnosed with major depressive disorder. Ongoing clinical trials are underway to uncover the unique position of neurobiotic PS128 in psychiatric disorders, seeking deeper insights to support and enhance mental well-being. About Neurobiotics Neurobiotics (or psychobiotics) offer a novel and low-risk alternative in providing comprehensive aid for individuals dealing with neurological conditions such as ASD and PD. Unlike common probiotics focused solely on digestion, neurobiotics encompass strains with neurological activity that support neurological health. Neurobiotic PS128 leverages the GBA to alleviate neurological symptoms associated with mood regulation, movement, learning, memory processes, and cognitive function. PS128 is safe for human supplementation, and no adverse events related to the PS128 intervention were found clinically. About Bened Life Bened Life is dedicated to providing science-backed, pharmaceutical-grade, gut-brain probiotics that support mental and neurological health. Neuralli Medical Probiotic, which contains the clinical dose of L. plantarum PS128, is a product attributed to the brand Bened Life. Visit benedlife.com to learn more about Neuralli. Contact infoName: Eva LeeEmail: international@benedlife.com
BRAUNSCHWEIG, Germany, Jan. 25, 2024 /PRNewswire/ -- MPI Corporation's Advanced Semiconductor Test (AST) Division, a pioneer in on-wafer testing solutions, today announced a landmark achievement in RF calibration technology. Collaborating with the Physikalisch-Technische Bundesanstalt (PTB) in Germany, the division has successfully achieved full traceability in characterizing a commercially-available calibration substrate up to 110 GHz and set a new industry benchmark. This achievement, spearheaded by Dr. Andrej Rumiantsev, Director of RF Technology at MPI-AST, represents a significant leap for the entire RF product line provided by MPI product line. The fully traceable characterization paves the way for more accurate, reliable, and universally accepted high-frequency measurements, essential for cutting-edge technologies like 5G. "Attaining full traceability in RF calibration at such high frequencies is a testament to our dedication to precision and quality," said Dr. Rumiantsev. "This breakthrough is an outcome of our long-term cooperation with PTB. Is not just an advancement for MPI-AST but a significant stride for the entire microwave measurement community, semiconductor and telecommunications industries." Dr Gia Ngoc Phung (PTB, Germany) passes the TCS-050-100-W Calibration Substrates Certificate to MPI Corporation TCS-050-100-W Calibration Substrates Certificate "Establishing the national standards for RF system calibration at the wafer-level is the goal that PTB had been working towards for several years," said Dr. Uwe Arz, the head of the On-Wafer Scattering Parameters group of PTB, Germany. "We are proud to announce the solution for transferring the traceability chain to the commercial calibration substrate from MPI for the first time in the industry." MPI-AST's latest achievement underscores its role as a leader in the semiconductor test industry, promising to open new avenues in high-frequency testing and solidifying its position as a market leader. For more information, please refer to: World's first calibration certificates for on-wafer measurements - PTB.de Traceable Lumped-Element Calibrations up to 110 GHz on Commercial Calibration Substrates | IEEE Conference Publication | IEEE Xplore About MPI CorporationFounded in 1995 and headquartered in Hsinchu, Taiwan, MPI Corporation is a global technology leader in the testing of Semiconductors, Light Emitting Diodes (LED), Photo Detectors, Lasers, Materials Research, Aerospace, Automotive, Fiber Optic, Electronic Components, and more. MPI's five main business sectors include Probe Card, Photonics Automation, Advanced Semiconductor Test, Thermal Test, and Celadon Systems Divisions. MPI offers a wide-ranging portfolio of products and services, from advanced probe card technologies, mass production and engineering probe systems, testers, material handlers, inspection systems, and thermal air stream systems. Many of these products are accompanied by state-of-the-art Calibration and Test & Measurement software suites. MPI's diverse product portfolio and expertise in leading edge technologies creates a healthy environment for employee growth and retention. With the cross-pollination of technologies and talent, we are committed to delivering long-term value to enhance the competitiveness of our customers. MPI is the first Taipei Exchange (TPEx) listed probe card company in Taiwan. For more information please visit: mpi-corporation.com About PTBPTB, with the main site situated in Braunschweig, is the National Metrology Institute of Germany and measures with the highest accuracy and reliability. PTB uses metrology as the core competence for the benefit of society, trade and industry, and science.
SINGAPORE, Jan. 25, 2024 /PRNewswire/ -- Mars Wrigley, a global leader in the treats and snacks category and a business division of Mars Incorporated, has announced the appointment of two senior executives to bolster the strength of its Asia Leadership Team, as it pursues quality growth in a region that is poised for double-digit growth, and home to nearly five billion people. Kristi Kee is the Sales and Operations (S&OP) and Activity Management Director for Asia, and Huyen Bui is the General Manager for Vietnam. Both leaders bring more than two decades of deep experience in each of their functional areas and will join the Mars Wrigley Asia Leadership Team. (Left) Kristi Kee, Sales and Operations (S&OP) and Activity Management Director for Asia, (Right) Huyen Bui, General Manager for Vietnam Both Kristi and Huyen report directly to Kalpesh Parmar, General Manager for Mars Wrigley Asia. Following his transition from Mars Wrigley in India to Mars Wrigley Asia, Kalpesh has leveraged his experience in business strategy and brand building to drive growth while focusing on talent development and engagement. The appointment of both Kristi and Huyen underscores the company's commitment to fostering gender diversity and representation in key leadership roles that reflects the race and ethnicities of the region it operates in. In her role as S&OP and Activity Management Director for Asia at Mars Wrigley, Kristi plays a pivotal role in leading a diverse and engaged team across the region to transform Asia's sales planning and commercial operations. Kristi's robust commercial background and strategic agility is demonstrated through her global experience in previous roles, including spearheading the Integrated Business Planning (IBP) process across 80 countries which led to demand forecasting improvements and resource optimization. Nurturing local markets for success As the General Manager for Vietnam, Huyen will play a critical role in accelerating quality growth to optimize share growth, distribution and profitability in this strategic market of opportunity for Mars Wrigley Asia. She has joined the company since January this year and brings with her 22 years of experience in various leadership roles within the FMCG industry. A seasoned commercial leader, Huyen has made significant contributions across the Home Care, Snack Food and Beverage segments in her previous roles. As General Manager of Vietnam, she will also focus on nurturing local talent and strengthen Mars Wrigley's brand presence amongst Vietnamese consumers. Kalpesh Parmar, General Manager at Mars Wrigley Asia said, "We are delighted to welcome two female leaders - Kristi and Huyen - to the Asia team. As the Mars Wrigley Asia business is expected to fuel the future growth for the company, I am confident that their strong credentials in transformational leadership and commercial acumen will accelerate Asia's trajectory to achieve our billion-dollar ambition by ensuring our iconic brands such as M&M'S, Snickers, Doublemint and Skittles inspire moments of everyday happiness." About Mars, Incorporated For more than a century, Mars, Incorporated has been driven by the belief that the world we want tomorrow starts with how we do business today. This common purpose unites our 140,000+ Associates. It is at the center of who we are as a global, family-owned business, and it fuels how we are transforming, innovating, and evolving to make a positive impact on the world. Every year, our diverse and expanding portfolio of quality confectionery, food, and pet care products and services delight millions of people and supports millions of pets. With almost $45 billion in annual sales, we produce some of the world's best-loved brands including Ben's Original™, CESAR®, Cocoavia®, DOVE®, EXTRA®, KIND®, M&M's®, SNICKERS®, PEDIGREE®, ROYAL CANIN®, and WHISKAS®. We are creating a better world for pets through nutrition, breakthrough programs in diagnostics, wearable health monitoring, DNA testing, pet welfare and comprehensive veterinary care with AniCura, BANFIELD™, BLUEPEARL™, Linnaeus and VCA™. We know we can only be truly successful if our partners and the communities in which we operate prosper. The Mars Five Principles – Quality, Responsibility, Mutuality, Efficiency and Freedom – inspire our Associates to act every day to help create a better world tomorrow in which the planet, its people and pets can thrive. For more information about Mars, please visit www.mars.com. Join us on Facebook, Twitter, Instagram, LinkedIn and YouTube.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
